High dose intravenous methylprednisolone treatment is effective and safe in the treatment of relapses in multiple sclerosis, but the long term effects are unclear. Pharmacokinetics are almost unknown, but may be very important for the understanding of the clinical and paraclinical effects. In view of what is known now, IVMP should have a prominent place in basic and clinical MS research.
1 Barkhoff, Hommes OR, Schelten Ph, Valk J. (1991) Quantitative MRI changes in Gadolinium-DTPA enhancement after high-dose intravenous Methylprednisolone in multiple sclerosis.Neurology41: 1219–1222.
2.
2 Barkhoff et al. (1992) A correlative trial of Gadolinium DTPA, MRI, EDSS, and CSF-MBP in relapsing multiple sclerosis patients treated with high-dose intravenous Methylprednisolone. Neurology42: 63–67.
3.
3 Frequin STFM, Barkhoff, Lamers KJB, Hommes OR. (1992) The effects of high-dose Methyl-prednisolone on Gadolinium-enhanced magnetic resonance imaging and cerebrospinal fluid measurements in multiple sclerosis.J Neuroimmunol4: 265–272.
4.
4 Barkhoff et al. (1994) Limited duration of the effect of Methylprednisolone on changes on MRI in multiple sclerosis. Neuroradiology36: 382–387.
5.
5 Frequin STFM et al. (1995) T-cell subsets in the cerebrospinal fluid and peripheral blood of multiple sclerosis patients treated with high-dose intravenous Methylprednisolone. Acta Neurol Scand88: 80–86.
6.
6 Beck RW et al. (1993) The optic neuritis group. The effect of corticosteriods for acute optic neuritis on the subsequent development of multiple sclerosis. New Eng J Med329: 1764–1769.
7.
7 Kupersmith MJ et al. (1994) Highdose corticoïds in multiple sclerosis. Neurology44: 1–4.
8.
8 Burham JA, Wrigh RR, Dreisbach J, Murray RS. (1991) The effect of high-dose steroïds on MRI Gadolinium enhancement in acute demyelinating lesions. Neurology41: 1349–1354.
9.
9 Miller DH et al. (1992) High dose steroids in acute relapses of multiple sclerosis: MRI evidence for a possible mechanism of therapeutic effect. J Neurol Neurosurg Psychiatry55: 450–453.
10.
10 Kesselring J et al. (1989) Quantitative magnetic resonance imaging in multiple sclerosis: the effect of high dose intravenous Methylprednisolone. J Neurol Neurosurg Psychiatry52: 14–17.
11.
11 Gasperini C et al. (1995) A longintudinal study of Gd-enhancing lesions in relapsing remitting multiple sclerosis: relationship between clinical relapses and steroid therapy. 11th ECTRIMS Congress. Jerusalem Sept. 3–6.
12.
12 Defer G-L et al. (1995) Methylprednisolone infusion during acute exacerbation of MS: Plasma and CSF concentrations. Eur Neurol35: 143–148.
13.
13 Frequin STFM et al. (1994) Follow-up study of MS patients treated with high-dose intravenous Methylprednisolone. Acta Neurol Scand90: 105–110.
14.
14 Jongen PJH, Smith CAJ, Borm G, Hommes OR. (1995) Methylprednisolone and osteoporosis in multiple sclerosis. 11th ECTRIMS Congress Jerusalem Sept.
15.
15 Engelen Van BGM, Pavelko KD, Rodriquez M, Promotion of central nervous system remyelination in Lysolecithin induced demyelination (this volume).
16.
16 Gasperini C et al. (1995) Association of high dose steroid with recombinant beta-interferon therapy: prolonged effect on Gd-enhancing lesions in relapsing remitting MS. 11th ECTRIMS Congress Jerusalem Sept
